TherapeuticsMD Inc

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

TXMD$1.69-2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10-K summary

None.

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this 2023 10-K Report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 29, 2024.

THERAPEUTICSMD, INC.

/s/ Marlan D. Walker

Marlan D. Walker

Chief Executive Officer

Joseph Ziegler
Signature	Title
/s/ Marlan D. Walker	Chief Executive Officer
Marlan D. Walker	(Principal Executive Officer)
/s/ Joseph Ziegler	Principal Financial and Accounting Officer
/s/ Tommy G. Thompson	Chairman
Tommy G. Thompson
/s/ Cooper C. Collins	Director
Cooper C. Collins
/s/ Gail K. Naughton, Ph.D.	Director
Gail K. Naughton, Ph.D.
/s/ Justin Roberts	Director
Justin Roberts

INDEX TO FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm (PCAOB ID Number 52)	F-2
Report of Independent Registered Public Accounting Firm (PCAOB ID Number 248)	F-4
Consolidated Balance Sheets	F-5
Consolidated Statements of Operations	F-6
Consolidated Statements of Stockholders’ Equity (Deficit)	F-7
Consolidated Statements of Cash Flows	F-8
Notes to Consolidated Financial Statements	F-9

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.